Member access

4-Traders Homepage  >  Shares  >  SIX SWISS EXCHANGE AG  >  Roche Holding Ltd.       CH0012032048

 SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
Company
Roche Holding AG is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics.As a large biotech company, Roche has truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience.It is also a leader in in-vitro... 
Sector
Pharmaceuticals
Calendar
11/11 | 12:30pmPresentation
Surperformance© rating of Roche Holding Ltd.
Trading Rating : Investor Rating :
More about the company
Financials ( CHF)
Sales 2014 47 259 M
EBIT 2014 17 493 M
Net income 2014 11 865 M
Debt 2014 6 199 M
Yield 2014 2,90%
Sales 2015 49 641 M
EBIT 2015 18 831 M
Net income 2015 12 916 M
Debt 2015 70,3 M
Yield 2015 3,13%
PER 2014 20,42
PER 2015 18,55
EV / Sales 2014 5,28x
EV / Sales 2015 4,90x
Capitalization 243 117 M
More Financials
Latest news on ROCHE HOLDING LTD.
5d ago Weak Merck sales overshadow third quarter cost cuts
10/22 Roche to spend $3.2 billion on towering Basel base
10/22DJRoche to Spend CHF3 Billion in Research Center, Basel Headquarters
10/16 ROCHE : Pharmacyclics Enters Into Agreement with Roche to Evaluate IMBRUVICA® an..
10/16 New breast cancer drugs boost sales at Roche
10/15 ROCHE : FDA Approves Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulm..
10/13DJRoche Holding 3Q 2014 -- Forecast
10/08 ROCHE : FDA Grants Priority Review for Genentech’s Lucentis in Diabetic Re..
10/08 NOVARTIS : Shareholder group critical as Roche and Novartis chiefs top Swiss pay..
09/29 ROCHE : Genentech :’s Investigational Combination of Cobimetinib Plus Zelb..
09/28 ROCHE : Genentech :’s Perjeta Regimen Extended the Lives of People With an..
09/24 Adaptimmune raises $104 million to develop immune-system cancer drugs
More news
Comments 
Advertisement
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF